Gilead’s Hep C Drug Receives Approval In Japan - Analyst Reactions By: TalkMarkets March 31, 2015 at 11:58 AM EDT Sovaldi becomes the first Gilead drug available in Japan. Overall analyst consensus is Strong Buy. Read More >> Related Stocks: Gilead Sciences